Baillie Gifford & CO Procept Bio Robotics Corp Transaction History
Baillie Gifford & CO
- $128 Billion
- Q3 2025
A detailed history of Baillie Gifford & CO transactions in Procept Bio Robotics Corp stock. As of the latest transaction made, Baillie Gifford & CO holds 858,831 shares of PRCT stock, worth $29.5 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
858,831
Previous 876,363
2.0%
Holding current value
$29.5 Million
Previous $50.5 Million
39.28%
% of portfolio
0.02%
Previous 0.04%
Shares
5 transactions
Others Institutions Holding PRCT
# of Institutions
290Shares Held
45.3MCall Options Held
236KPut Options Held
91.9K-
Vanguard Group Inc Valley Forge, PA5.25MShares$180 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.49MShares$120 Million0.0% of portfolio
-
Alliancebernstein L.P. New York, NY2.16MShares$74.2 Million0.04% of portfolio
-
Chicago Capital, LLC1.57MShares$53.9 Million1.39% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD1.53MShares$52.5 Million0.06% of portfolio
About PROCEPT BioRobotics Corp
- Ticker PRCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 44,592,300
- Market Cap $1.53B
- Description
- PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aqu...